The next generation of medicines won’t consist only of brand-new discoveries.
It will also include better versions of the medicines patients already depend on.
Some of the biggest advances in medicine don’t come from discovering entirely new drugs. They come from making existing ones easier to take, faster to administer, safer, and more effective.
A new proposal from the Centers for Medicare and Medicaid Services could make those improvements far less common.
The agency wants to treat some newer versions of existing medicines as though they were the original drug when deciding when government price controls should begin.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
CMS Undermining Next Generation of Medicines
Sally C. Pipes
The next generation of medicines won’t consist only of brand-new discoveries.
It will also include better versions of the medicines patients already depend on.
Some of the biggest advances in medicine don’t come from discovering entirely new drugs. They come from making existing ones easier to take, faster to administer, safer, and more effective.
A new proposal from the Centers for Medicare and Medicaid Services could make those improvements far less common.
The agency wants to treat some newer versions of existing medicines as though they were the original drug when deciding when government price controls should begin.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.